Literature DB >> 17982429

Type 1 diabetes as a relapsing-remitting disease?

Matthias von Herrath1, Srinath Sanda, Kevan Herold.   

Abstract

Chronic immunological processes that underlie persistent viral infections and autoimmune disorders such as multiple sclerosis can be relapsing-remitting in nature. The progressive loss of beta-cell mass during the development of autoimmune type 1 diabetes (T1D) can also be non-linear, but the exact nature and kinetics of the immunological processes that govern T1D are not known. Here, we propose that the immunological process that is at the root of T1D is relapsing-remitting in nature and discuss the unresolved controversies and therapeutic implications of this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982429     DOI: 10.1038/nri2192

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  112 in total

1.  Association of major histocompatibility complex class 1 chain-related gene a dimorphism with type 1 diabetes and latent autoimmune diabetes in adults in the Algerian population.

Authors:  Rachida Raache; Khadidja Belanteur; Habiba Amroun; Amel Benyahia; Amel Heniche; Malha Azzouz; Safia Mimouni; Thibaud Gervais; Dominique Latinne; Aissa Boudiba; Nabila Attal; Mohamed Cherif Abbadi
Journal:  Clin Vaccine Immunol       Date:  2012-02-08

Review 2.  Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host.

Authors:  Didier Hober; Pierre Sauter
Journal:  Nat Rev Endocrinol       Date:  2010-03-30       Impact factor: 43.330

3.  Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology.

Authors:  Ken T Coppieters; Bart O Roep; Matthias G von Herrath
Journal:  Semin Immunopathol       Date:  2010-12-18       Impact factor: 9.623

Review 4.  Blood-based signatures in type 1 diabetes.

Authors:  Susanne M Cabrera; Yi-Guang Chen; William A Hagopian; Martin J Hessner
Journal:  Diabetologia       Date:  2015-12-23       Impact factor: 10.122

5.  Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial.

Authors:  Gadi Lalazar; Meir Mizrahi; Ilit Turgeman; Tomer Adar; Ami Ben Ya'acov; Yehudit Shabat; Assy Nimer; Nila Hemed; Lidya Zolotarovya; Yoav Lichtenstein; Nadya Lisovoder; Sarit Samira; Itamar Shalit; Ronald Ellis; Yaron Ilan
Journal:  J Clin Immunol       Date:  2015-04-17       Impact factor: 8.317

6.  Continuum model of T-cell avidity: Understanding autoreactive and regulatory T-cell responses in type 1 diabetes.

Authors:  Majid Jaberi-Douraki; Massimo Pietropaolo; Anmar Khadra
Journal:  J Theor Biol       Date:  2015-08-10       Impact factor: 2.691

7.  Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 8.  Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.

Authors:  Xiaolun Huang; Daniel J Moore; Robert J Ketchum; Craig S Nunemaker; Boris Kovatchev; Anthony L McCall; Kenneth L Brayman
Journal:  Endocr Rev       Date:  2008-07-29       Impact factor: 19.871

9.  Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 10.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.